U.S., Aug. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07148336) titled 'Identification of Chemotherapy-induced Peripheral Neuropathy' on Aug. 22.
Brief Summary: The main goal of this trial is to identify the optimal cut-off score of a Scoring System to discriminate between moderate to severe chemotherapy-induced peripheral neuropathy (CIPN) and no CIPN in breast cancer survivors previously treated with taxane-based chemotherapy and adjuvant radiotherapy.
Study Start Date: Nov. 01, 2025
Study Type: INTERVENTIONAL
Condition:
Breast Cancer
Intervention:
OTHER: Symptom-based scoring system
The patients will be asked to complete the self-evaluation of symptoms and signs of neuropathy using a Neuropath...